Texas Liver Institute

San Antonio, Texas 78215-2100

5 studies enrolling now · 49 studies all time

What they study most

Advanced or Metastatic Solid Tumor, Alagille Syndrome, Ascites Hepatic, Cirrhosis, Cirrhosis, Liver, Compensated Cirrhosis, Fatty Liver, Focal Segmental Glomerulosclerosis (FSGS), HCV, HCV Infection, Healthy, Healthy Volunteers

Studies at this site

• Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions — Recruiting now
• A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment — Recruiting now
• Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment — Recruiting now
• Radiprodil in Participants With Hepatic Impairment — Recruiting now
• Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics — Recruiting now
• Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 — Recruiting now
• GT-032 Belapectin Hepatic Impairment — Completed
• Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome — Running, not enrolling
• A Study of LY3502970 in Participants With Impaired and Normal Liver Function — Completed
• Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis — Completed
• Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls — Completed
• Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function — Completed
• Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment — Completed
• A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants. — Completed
• A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4 — Stopped early
• Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment — Completed
• A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis. — Completed
• Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Running, not enrolling
• Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment — Completed
• A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function — Completed
• Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis — Completed
• A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function — Completed
• Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease — Completed
• An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143 — Completed
• A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials — Stopped early
• BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH — Completed
• Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis — Stopped early
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis — Completed
• Safety, Tolerability and Pharmacodynamics of SYNB1020 — Stopped early
• A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) — Completed
• A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) — Completed
• TD-6450 MAD Study in HCV Infected Subjects — Completed
• Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis — Completed
• Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency — Completed
• Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) — Completed
• Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment — Completed
• Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment — Completed
• Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection — Completed
• Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection — Completed
• A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects — Completed
• Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants — Completed
• A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants — Withdrawn before enrolling
• Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus — Completed
• UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects — Completed
• BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C — Completed
• Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) — Completed
• UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis — Completed
• Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial — Completed